仁和藥業(000650.SZ):擬斥8.22億元投建明月仁和礦泉水廠和中藥前處理及提取項目
格隆匯7月3日丨仁和藥業(000650.SZ)宣佈,根據公司經營發展戰略的需要,為增強公司傳統醫藥生產能力和可持續發展能力,優化公司的產業結構,提升公司生產經營規模及經濟效益,同時確保公司生產業務滿足國家環保政策的規定及社會公眾需求,公司擬使用自有資金投資明月仁和礦泉水廠項目和中藥前處理及提取項目。
其中明月仁和礦泉水廠項目擬新建年產50萬噸(其中一期年產30萬噸)礦泉水廠房、生產線及配套設施等工程,投資主體為江西明月仁和健康產業有限公司,總投資5億元左右,其中一期投資約3.45億元;中藥前處理及提取項目擬新建集中藥前處理、中藥打粉、中藥提取、技術研發及銷售等功能為一體的綜合性工程,投資主體為江西藥都仁和製藥有限公司,計劃投資3.26億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.